Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business UpdateGlobeNewsWire • 11/14/22
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHDGlobeNewsWire • 11/01/22
Cingulate Announces Agreement with Societal CDMO and Provides Clinical UpdateGlobeNewsWire • 10/24/22
Cingulate Presents Data for Its Triple-Release Buspirone Product Candidate: CTx-2103GlobeNewsWire • 09/19/22
Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business UpdateGlobeNewsWire • 08/11/22
Kansas City Business Journal Names Cingulate's Louis G. Van Horn a 2022 Chief Financial Officer of the YearGlobeNewsWire • 07/25/22
Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety DisordersGlobeNewsWire • 06/23/22
Cingulate to Present at Diamond Equity Research 2022 Virtual Emerging Growth InvitationalGlobeNewsWire • 06/17/22
Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety DisordersGlobeNewsWire • 05/24/22
Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business UpdateGlobeNewsWire • 05/12/22
Cingulate Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Clinical and Business UpdateGlobeNewsWire • 03/10/22
Cingulate Outlines Plan For Pivotal Attention Deficit/Hyperactivity Disorder StudiesBenzinga • 02/08/22
Cingulate Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD)GlobeNewsWire • 02/08/22
Aegis Capital Corp. acted as Lead Bookrunning Manager on a $25 Million Initial Public Offering of Common Stock for Cingulate Inc. (NASDAQ: CING)Accesswire • 12/10/21